

AOK	LKK	BKK	IKK	VdAK	AEV	Knappschaft	Privat	Re. an K-Haus
Name, Vorname des Versicherten geb. am								
Kassen-Nr.			Versicherten-Nr.			Status		
Vertragsarzt Nr.		VK gültig bis			Datum			

Antrag auf molekularpathologische Begutachtung

(mit Einverständnis des Patienten)

Zentrum für Pathologie Allgäu (ZfPA) Med. Versorgungszentrum am Klinikum Kempten

PD Dr. med. Konrad Aumann und KollegInnen

Postfach 2122, 87411 Kempten
Robert-Weixler-Str. 48, 87439 Kempten
Tel. 0831 530-2180 | Fax 530-2170

pathologie-info@klinikverbund-allgaeu.de
www.patho-kempten.de



Dieser Anforderungsbogen ersetzt nicht den Überweisungsschein bei Kassenpatienten.

Ambulant Privat Stationär

Klinische Angaben:

Diagnose (ICD 10):

Prädiktive und prognostische Analysen (organspezifisch)

- | | | | |
|---|---|---|--|
| <input type="radio"/> Lungenkarzinom | <input type="radio"/> Mikrosatelliten-Instabilität (MSI Panel) | <input type="radio"/> PD-L1 (IHC) | <input type="radio"/> BRAF-Mutationen (Exon 11, 15) |
| <input type="radio"/> ALK-Translokation [t(2q23)] | <input type="radio"/> BRAF-Mutationen (Exon 15) | <input type="radio"/> MSI-/MMR-Diagnostik | <input type="radio"/> Urothelkarzinom |
| <input type="radio"/> RET-Translokation [t(10q11)] | <input type="radio"/> MLH1-Promotor Methylierung* | <input type="radio"/> Ovarialkarzinom | <input type="radio"/> FGFR1/2/3-Fusionen |
| <input type="radio"/> ROS-Translokation [t(6q22)] | <input type="radio"/> Gastrointestinaler Stromatumor / GIST | <input type="radio"/> BRCA1/2 | <input type="radio"/> FGFR1/2/3-Mutationen (Exon 7, 9, 14, 16, 18) |
| <input type="radio"/> MET-Amplifikation | <input type="radio"/> KIT-Mutationen (Exon 2, 9-11, 13-15, 17, 18) | <input type="radio"/> HRD-Analyse* | <input type="radio"/> HER2-Analyse [ERBB2] |
| <input type="radio"/> NRG1-Fusionen | <input type="radio"/> PDGFRA-Mutationen (Exon 12, 14, 15, 18) | <input type="radio"/> Prostatakarzinom | <input type="radio"/> PD-L1 (IHC) |
| <input type="radio"/> BRAF-Mutationen (Exon 11, 15) | <input type="radio"/> Malignes Melanom | <input type="radio"/> BRCA1/2 | <input type="radio"/> Cholangiokarzinom |
| <input type="radio"/> EGFR-Mutationen (Exon 3, 7, 15, 18-21) | <input type="radio"/> BRAF-Mutationen (Exon 11, 15) | <input type="radio"/> ATM-Mutation | <input type="radio"/> FGFR1/2/3-Fusionen |
| <input type="radio"/> EGFR-T790M-Mutation (Exon 20) | <input type="radio"/> KIT-Mutationen (Exon 2, 9-11, 13-15, 17, 18) | <input type="radio"/> PTEN-Expressionsanalyse (IHC) | <input type="radio"/> IDH1/2-Mutationen (Exon 2, 4) |
| <input type="radio"/> HER2-Mutationen (Exon 20) | <input type="radio"/> NRAS-Mutationen (Exon 2, 3, 4) | <input type="radio"/> HRD-Analyse* | <input type="radio"/> BRAF-Mutationen (Exon 11, 15) |
| <input type="radio"/> KRAS-Mutationen (Exon 2, 3, 4) | <input type="radio"/> Mammakarzinom | <input type="radio"/> Pankreaskarzinom | <input type="radio"/> KRAS-Mutationen (Exon 2, 3, 4) |
| <input type="radio"/> PIK3CA-Mutationen (Exon 2, 5, 7, 8, 10, 14, 19, 21) | <input type="radio"/> HER2-Analytik 17q12 [ERBB2] | <input type="radio"/> BRCA1/2 | <input type="radio"/> HER2-/ERBB2-Mutationen (Exon 19, 20, 21) |
| <input type="radio"/> MET Ex 14 Skipping Variante | <input type="radio"/> PIK3CA-Mutationen (Exon 2, 5, 7, 8, 10, 14, 19, 21) | <input type="radio"/> KRAS-Mutationen (Exon 2, 3, 4) | <input type="radio"/> BRCA1/2-Mutationen |
| <input type="radio"/> KEAP1-Mutationen (Exon 2-6) | <input type="radio"/> ESR1-Mutationen | <input type="radio"/> NRG1-Fusionen | <input type="radio"/> PD-L1 (IHC) |
| <input type="radio"/> TP53-Mutationen (Exon 2, 4-8, 10) | <input type="radio"/> BRCA1/2 | <input type="radio"/> Kopf-Hals Tumoren | <input type="radio"/> MSI-/MMR-Diagnostik |
| <input type="radio"/> STK11-Mutationen (Exon 1, 4-6, 8) | <input type="radio"/> PD-L1 (IHC) | <input type="radio"/> FGFR-Fusionen (8p11) | <input type="radio"/> Endometriumkarzinom |
| <input type="radio"/> PD-L1 (IHC) | <input type="radio"/> RNA-Expressionsanalyse (Endo-predict)* | <input type="radio"/> EGFR-Mutationen (Exon 3, 7, 15, 18-21) | <input type="radio"/> MSI-/MMR-Diagnostik |
| <input type="radio"/> Kolorektales Karzinom | <input type="radio"/> Magen-/Ösophaguskarzinom | <input type="radio"/> RAS-Mutationen (Exon 2, 3, 4) | <input type="radio"/> TP53-Mutationen |
| <input type="radio"/> KRAS-Mutationen (Exon 2, 3, 4) | <input type="radio"/> HER2-Analytik 17q12 [ERBB2] | <input type="radio"/> PIK3CA-Mutationen (Exon 2, 5, 7, 8, 10, 14, 19, 21) | <input type="radio"/> POLE-Mutationen (Exon 9-14) |
| <input type="radio"/> NRAS-Mutationen (Exon 2, 3, 4) | <input type="radio"/> EBV (EBER-ISH) | <input type="radio"/> EBV (EBER-ISH) | <input type="radio"/> L1CAM-Expressionsanalyse (IHC) |
| <input type="radio"/> BRAF-Mutationen (Exon 15) | <input type="radio"/> Lynch-Diagnostik | <input type="radio"/> Schilddrüsenkarzinom | |
| <input type="radio"/> PIK3CA-Mutationen (Exon 9, 20) | <input type="radio"/> MMR-Proteine (IHC: MLH1, MSH2, MSH6, PMS2) | <input type="radio"/> RET-Fusionen (10q11) | |
| <input type="radio"/> HER2-Analytik (17q12 [ERBB2]) | | <input type="radio"/> RET-Mutationen (Exon 10, 11, 13, 15, 16) | |
| <input type="radio"/> PD-L1 (IHC) | | | |

* in Kooperation mit externen Laboren

Somatische Mutations-/Fusionsanalytik (NGS Panel-Diagnostik)

- Illumina Cancer Hotspot:** ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL
- QIAseq Targeted DNA Panel (nNGM v2):** ALK, BRAF, CTNNB1, EGFR, ERBB2, IDH1, IDH2, FGFR1, FGFR2, FGFR3, FGFR4, KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN, TP53, ROS1, NTRK1, NTRK2, NTRK3, RET, HRAS, STK11, KEAP1
- RNA-Fusionsanalyse (QIAseq Targeted RNAscan Panel (nNGM)):** ALK, MET, BAG4, MPRIP, BRAF, MRPS14, CCDC6, NRG1, CD74, NTRK1, CIAO1, NTRK2, COPA, NTRK3, CUX1, RAD51, EGFR, RET, EML4, ROS1, ETV6, SDC4, EZR, SLC34A2, FGFR1, STRN, FGFR2, TACC3, FGFR3, TFG, GOPC, TPM3, HIP1, TPR, KIF5B, TRIM33, KLC1, UBE3C, LRIG

In-situ-Hybridisierungen zur Evaluation von Genrearrangements / Sonstiges:

- | | | |
|--|--|--|
| Sonde (Beispiel) | <input type="radio"/> EWSR1 bap [22q12] (Ewing Sarkom) | <input type="radio"/> CCND1-bap [11q13] (Mantelzelllymphom) |
| <input type="radio"/> MDM2 [12q15] (Liposarkom) | <input type="radio"/> HER2/CEP17 [17q11] (Mamma) | <input type="radio"/> 19q13/19p13 (Gliome) |
| <input type="radio"/> DDIT3 bap [12q13] (Liposarkom) | <input type="radio"/> SS18 bap [18q11] (synoviales Sarkom) | <input type="radio"/> 1p36/1q25 (Gliome) |
| <input type="radio"/> FUS bap [16p11] (Liposarkom) | <input type="radio"/> MET-Amplifikation (Lungenkarzinom) | <input type="radio"/> EBV EBER-ISH (Magenkarzinom, Lymphome) |

Sonstiges: _____

Stempel Arzt / Klinik

Unterschrift